×

CD37 immunotherapeutics and uses thereof

  • US 10,307,481 B2
  • Filed: 07/25/2006
  • Issued: 06/04/2019
  • Est. Priority Date: 07/25/2005
  • Status: Active Grant
First Claim
Patent Images

1. A humanized or chimeric CD37-specific immunoglobulin binding protein, comprising:

  • (a) a light chain variable region comprising, from amino terminus to carboxy terminus, a first framework region, a light chain CDR1 comprising the amino acid sequence set forth in SEQ ID NO;

    61, a second framework region, a light chain CDR2 comprising the amino acid sequence set forth in SEQ ID NO;

    64, a third framework region, a light chain CDR3 comprising the amino acid sequence set forth in SEQ ID NO;

    66, and a fourth framework region; and

    (b) a heavy chain variable region comprising, from amino terminus to carboxy terminus, a first framework region, a heavy chain CDR1 comprising the amino acid sequence set forth in SEQ ID NO;

    63, a second framework region, a heavy chain CDR2 comprising the amino acid sequence set forth in SEQ ID NO;

    65, a third framework region, a heavy chain CDR3 comprising the amino acid sequence set forth in SEQ ID NO;

    69, and a fourth framework region;

    wherein the binding protein binds human CD37.

View all claims
  • 8 Assignments
Timeline View
Assignment View
    ×
    ×